secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001798749-24-000036
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics cuts 78% of workforce after halting AV-101 trial
----------------------------------------------------------------------

- Reduction follows shutdown of Phase 2b/3 trial of AV-101 and long-term extension study.
- First wave terminates 39 employees (78% of workforce); nearly all remaining staff to follow.
- Estimated severance costs of $5.6 million, expected in Q3 and Q4 2024.
- Severance contingent on separation agreement with general release of claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000036/0001798749-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000036/tmb-20240625x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer